2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-103238
    RSVA405 140405-36-3 99.72%
    RSVA405 is a potent, orally active activator of AMPK, with an EC50 of 1 μM. RSVA405 facilitates CaMKKβ-dependent activation of AMPK, inhibits mTOR, and promotes autophagy to increase Aβ degradation. RSVA405 has anti-inflammatory effects through the inhibition of STAT3 function. RSVA405 can also be used for the research of obesity.
    RSVA405
  • HY-103345
    2-MPPA 254737-29-6 98.0%
    2-MPPA (GPI-5693) is an orally active and selective glutamate carboxypeptidase II (GCP II; PSMA) inhibitor with an IC50 of 90 nM.
    2-MPPA
  • HY-107664
    SR 142948 184162-64-9 99.16%
    SR 142948 is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC50s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. SR 142948 antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC50 of 3.9 nM. SR 142948 blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 shows blood-brain permeability and can be used in study of psychiatric disorders.
    SR 142948
  • HY-107757
    GMQ hydrochloride 5361-15-9 99.86%
    GMQ (hydrochloride) is a ASIC (acid-sensing ion) channel activator with an EC50 value of 1.83 mM for ASIC3 at pH 7.4. GMQ (hydrochloride) opens only ASIC3 but no other ASICs at pH 7.4. GMQ (hydrochloride) can be used for neurological disease research.
    GMQ hydrochloride
  • HY-109052
    Atabecestat 1200493-78-2 99.77%
    Atabecestat (JNJ-54861911) is a potent brain-penetrant and orally active β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor, achieves robust and high CSF Aβ reduction. Atabecestat s tolerated and displays a sustained pharmacokinetic (PK) and pharmacodynamic (PD) characteristics. Atabecestat has the potential for Alzheimer's Disease treatment.
    Atabecestat
  • HY-112798
    PH-002 1311174-68-1 98.78%
    PH-002 is an inhibitor of apolipoprotein (apo) E4 intramolecular domain interaction in neuronal cells that could rescue impairments of mitochondrial motility and neurite outgrowth.
    PH-002
  • HY-113303
    FAPy-adenine 5122-36-1 99.86%
    FAPy-adenine is an oxidized DNA base. Fapy-adenine shows an increased trend levels in the Alzheimer's disease brain. Oxidized nucleosides are biochemical markers for tumors, aging, and neurodegenerative diseases.
    FAPy-adenine
  • HY-113410
    3-Methylglutaric acid 626-51-7
    3-Methylglutaric acid is a non-selective inhibitor of mitochondrial function and Na+, K+-ATPase, with an inhibition rate of 30% on rat cortical synaptosomal Na+, K+-ATPase. 3-Methylglutaric acid can induce reactive oxygen species (ROS) generation, thereby causing oxidative damage and inhibiting mitochondrial redox potential and ion pump function of cell membranes. 3-Methylglutaric acid can be used to study the neuropathological mechanisms of metabolic diseases and the role of oxidative stress-mediated neuronal damage in neurodegeneration.
    3-Methylglutaric acid
  • HY-119591
    BPDBA 312281-74-6 99.40%
    BPDBA is a selective and noncompetitive betaine/GABA transporter (BGT-1) inhibitor with IC50s of 20 μM and 35 μM against human BGT-1 and mouse GAT2, respectively.
    BPDBA
  • HY-120348
    ML67-33 1443290-89-8 ≥99.0%
    ML67-33 is a selective activator of temperature- and mechano-sensitive K2P channels. ML67-33 rapidly and reversibly affects K2P2.1 (TREK-1) with EC50s of 36.3 μM and 9.7 μM in cell-free and HEK293 cells, respectively.
    ML67-33
  • HY-120619
    BMS-193885 186185-03-5 ≥99.0%
    BMS-193885 is a selective neuropeptide Y1 receptor antagonist (Ki=3.3 nM) that competitively blocks the receptor to inhibit NPY-mediated appetite regulation signaling pathways, reduce food intake and inhibit weight gain. BMS-193885 has good blood-brain barrier penetration and is mainly used in the study of obesity and related metabolic diseases.
    BMS-193885
  • HY-122273
    Pyrithiamine hydrobromide 534-64-5
    Pyrithiamine hydrobromide is a thiamine metabolic inhibitor that can act as a substrate for thiamine pyrophosphokinase. Pyrithiamine hydrobromide can be used in the research of nervous system diseases .
    Pyrithiamine hydrobromide
  • HY-122984
    Diquat dibromide 85-00-7 99.86%
    Diquat dibromide is a comprehensive herbicide. Diquat dibromide increases the production of ROS and triggers mitochondrial Autophagy. Diquat dibromide generates free radicals such as superoxide anions through redox cycles, which induce oxidative stress. Diquat dibromide is cytotoxic, reproductive, and neurotoxic. Diquat dibromide is used in cotton, soybean, and other crops to combat noxious weeds.
    Diquat dibromide
  • HY-124151
    Adenosine-2'-monophosphate 130-49-4 99.91%
    Adenosine-2'-monophosphate (2'-AMP) is converted by extracellular 2’,3'-CAMP. Adenosine-2'-monophosphate is further metabolized to extracellular adenosine (a mechanism called the extracellular 2’,3’-cAMP-adenosine pathway). Adenosine-2'-monophosphate inhibits LPS-induced TNF-α and CXCL10 production via A2A receptor activation.
    Adenosine-2'-monophosphate
  • HY-128121
    MLS1547 315698-36-3 99.94%
    MLS1547 is a highly efficacious G protein-biased dopamine D2 receptor (D2R) agonist (Ki=1.2 μM). MLS1547 stimulates D2R G protein-mediated signaling (EC50=0.37 μM in a calcium mobilization assay). MLS1547 acts as an antagonist for dopamine (DA)-stimulated β-arrestin recruitment to the D2R (IC50=9.9 μM).
    MLS1547
  • HY-135042
    CAY10614 1202208-36-3 98.87%
    CAY10614 is a potent TLR4 antagonist. CAY10614 inhibits the lipid A-induced activation of TLR4, with an IC50 of 1.675 μM. CAY10614 can improve survival of mice in lethal endotoxin shock model.
    CAY10614
  • HY-136181
    YNT-185 dihydrochloride 1804978-82-2 ≥98.0%
    YNT-185 dihydrochloride is a nonpeptide, selective orexin type-2 receptor (OX2R) agonist, with EC50s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 dihydrochloride ameliorates narcolepsy-cataplexy symptoms in mouse models.
    YNT-185 dihydrochloride
  • HY-136311
    NCT-504 1222765-97-0 ≥98.0%
    NCT-504 is a selective allosteric inhibitor of PIP4Kγ, with an IC50 of 15.8 μM. NCT-504 is potential for the research of Huntington's disease.
    NCT-504
  • HY-138559
    GW604714X 853953-65-8 98.49%
    GW604714X is a potent inhibitor of mitochondrial respiration supported by pyruvate but not other substrates. GW604714X is a highly specific mitochondrial pyruvate carrier (MPC) inhibitor with a Ki <0.1 nM. GW604714X also inhibits L-lactate transport by the plasma membrane monocarboxylate transporter (MCT1), but at concentrations more than 4 orders of magnitude greater than the MPC.
    GW604714X
  • HY-139048
    Fluoroethylnormemantine 1639210-26-6 98.0%
    Fluoroethylnormemantine, a derivative of Memantine, is an antagonist of the N-methyl-D-aspartate (NMDA) receptor. [18F]-Fluoroethylnormemantine can be used as a positron emission tomography (PET) tracer. Fluoroethylnormemantine exhibits anti-amnesic, neuroprotective, antidepressant-like and fear-attenuating effects.
    Fluoroethylnormemantine
Cat. No. Product Name / Synonyms Application Reactivity